Monday, October 14, 2019

ImaginAb Links With AstraZeneca, Pfizer, Takeda Pharmaceuticals

Los Angeles-based ImaginAb, which develops imaging technology being used in cancer assessment, says it has signed a multi-party collaboration agreement with AstraZeneca, Pfizer, and Takeda Pharmaceutical Company Limited. ImaginAb said the deal is focused on furthering clinical development of its CD8 ImmunoPET technology, which is used for quantitative assessment of the immunological status of each cancer lesion within a patient. Financial details of the agreement were not announced. ImaginAb said the agreement calls for the collaborators to guide a current ImaginAb-sponsored clinical trial that aims to evaluate the utility and value of CD8 ImmunoPET in immuno-oncology drug development. ImaginAb said those collaborators will gain early access to clinical and imaging data and collectively contribute to the post-trial data analysis.